TOT BIOPHARM is a clinical-stage biopharmaceutical company in Jiangsu, China that focuses on developing and commercializing oncology drugs and therapies. Founded 2009 in Suzhou, Jiangsu, China, focuses on developing oncology treatments. Their biomedical pilot research and commercial production use a disposable bioreactor system to strengthen production safety and reduce production costs. The company has independently developed a new cell expansion technology, namely "perfusion-batch mixed culture technology", which is suitable for the commercial production of monoclonal antibodies. This technology can be used for seed expansion in a 25-liter bioreactor without the use of The 50-liter, 200-liter and 500-liter bioreactors are directly expanded to 2,000-liter bioreactors, thereby saving capital expenditure, facility space, production costs and production time.
TOT BIOPHARM has established three integrated technology platforms, including: The Therapeutic Monoclonal Antibody and Antibody Drugs Conjugates(ADC) Technology Platform, The Gene Engineering Based Therapeutics Technology Platform and The Innovative Drug Delivery Technology Platform. Therapeutic monoclonal antibody and ADC drug technology platform integrated the company's R&D and production capacity, enabling the company to develop a series of antibody drugs and ADC. The therapeutic technology platform based on gene engineering integrates anti-tumor immunotherapy, gene therapy and viral therapy, and carries out research and development and production of recombinant virus vector systems for tumor targets. The delivery technology platform includes advanced targeted liposome drug delivery systems that have key embedding technologies for both hydrophobic and hydrophilic compounds to avoid the breakdown of the embedded composition and to release the embedded composition at the intended target site.